METCrusaders· @metcrusaders · X·· 2 天前评分70
正文 · 机器翻译
感谢你列出这些数据，@HHorinouchi。MET 患者一年总生存率 70% vs. 53% 尤为突出。#lcsm #ESMO26
10 浏览 · 0 赞 · 0 转发 · 0 回复
🔥SAFFRON: Osimertinib + savolitinib vs platinum-pemetrexed in EGFR-mutated NSCLC with MET overexpression/amp post-osimertinib 🆙 @NEJM #ESMO26 ☑Phase 3 RCT; N=338; 12-mo PFS 36 vs 10% (HR 0.55, p<0.001); 12-mo OS 70 vs 53% (HR 0.68, p=0.01) 🎙Dr. Shun Lu @nicogirardcurie #LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders https://www.nejm.org/doi/full/10.1056/NEJMoa2611335在 X 查看被引用的帖子
来源：METCrusaders · x.com